Concurrent Chemotherapy and Pulsed High-Intensity Focused Ultrasound Therapy for the Treatment of Unresectable Pancreatic Cancer: Initial Experiences
Open Access
- 1 January 2011
- journal article
- Published by The Korean Society of Radiology in Korean Journal of Radiology
- Vol. 12 (2), 176-186
- https://doi.org/10.3348/kjr.2011.12.2.176
Abstract
This study was performed to evaluate the potential clinical value of concurrent chemotherapy and pulsed high intensity focused ultrasound (HIFU) therapy (CCHT), as well as the safety of pulsed HIFU, for the treatment of unresectable pancreatic cancer. Twelve patients were treated with HIFU from October 2008 to May 2010, and three of them underwent CCHT as the main treatment (the CCHT group). The overall survival (OS), the time to tumor progression (TTP), the complications and the current performance status in the CCHT and non-CCHT groups were analyzed. Nine patients in the non-CCHT group were evaluated to determine why CCHT could not be performed more than twice. The OS of the three patients in the CCHT group was 26.0, 21.6 and 10.8 months, respectively, from the time of diagnosis. Two of them were alive at the time of preparing this manuscript with an excellent performance status, and one of them underwent a surgical resection one year after the initiation of CCHT. The TTP of the three patients in the CCHT group was 13.4, 11.5 and 9.9 months, respectively. The median OS and TTP of the non-CCHT group were 10.3 months and 4.4 months, respectively. The main reasons why the nine patients of the non-CCHT group failed to undergo CCHT more than twice were as follows: pancreatitis (n = 1), intolerance of the pain during treatment (n = 4), palliative use of HIFU for pain relief (n = 1) and a poor physical condition due to disease progression (n = 3). No major complications were encountered except one case of pancreatitis. This study shows that CCHT is a potentially effective and safe modality for the treatment of unresectable pancreatic cancer.Keywords
This publication has 18 references indexed in Scilit:
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic CancerJournal of Clinical Oncology, 2009
- Complications of High Intensity Focused Ultrasound for Patients with Hepatocellular CarcinomaTechnology in Cancer Research & Treatment, 2009
- High-Intensity Focused Ultrasound Therapy: an Overview for RadiologistsKorean Journal of Radiology, 2008
- Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology GroupJournal of Clinical Oncology, 2007
- Pulsed-High Intensity Focused Ultrasound and Low Temperature–Sensitive Liposomes for Enhanced Targeted Drug Delivery and Antitumor EffectClinical Cancer Research, 2007
- A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinomaCancer Chemotherapy and Pharmacology, 2007
- Complications of high intensity focused ultrasound in patients with recurrent and metastatic abdominal tumorsWorld Journal of Gastroenterology, 2007
- Gemcitabine Chemotherapy Versus 5-fluorouracil-based Concurrent Chemoradiotherapy in Locally Advanced Unresectable Pancreatic CancerPancreas, 2006
- Feasibility of US-guided High-Intensity Focused Ultrasound Treatment in Patients with Advanced Pancreatic Cancer: Initial ExperienceRadiology, 2005
- Pathological changes in human malignant carcinoma treated with high-intensity focused ultrasoundJapanese Journal of Clinical Oncology, 2001